JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating on Kura Oncology (NASDAQ:KURA) and maintained a $32 price target.
May 16, 2024 | 4:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating on Kura Oncology and maintained a $32 price target.
The reiteration of a Market Outperform rating and a maintained price target of $32 by JMP Securities is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100